{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"Subjects with hematologic improvement included those subjects with abnormally high values for neutrophil count, hemoglobin, or platelet count at Baseline determined to have consistently met the criteria of an improvement for those parameters for a period of at least 60 days during which the subject did not have a transfusion or exogenous cytokines.","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"},{"description":"Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.","id":"OG001","title":"Ofatumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Subjects With Abnormal Hematologic Values at Baseline","reportingStatus":"POSTED","timeFrame":"3 years","title":"Number of Subjects With Hematologic Improvements","type":"SECONDARY","unitOfMeasure":"Participants"}